In short
This article discusses an innovative clinical trial investigating a gene therapy approach for infants with Krabbe disease. The study, known as RESKUE, evaluates the safety and potential benefits of using an adeno-associated virus serotype rh10 containing the human GALC gene (AAVrh10-hGALC) in combination with stem cell transplantation. This groundbreaking research aims to improve treatment outcomes for children affected by this rare genetic disorder.
At a glance
- Study Name
- RESKUE (Phase 1/2 Clinical Study)
- Investigational Product
- FBX-101 (AAVrh10-hGALC)
- Target Condition
- Infantile Krabbe Disease
- Primary Objective
- Evaluate safety of FBX-101 when administered intravenously after stem cell transplant
- Secondary Objective
- Collect evidence of potential therapeutic benefits
- Eligibility
- Infants aged 1 day to 12 months with diagnosed Krabbe disease
- Treatment Approach
- Gene therapy (FBX-101) combined with stem cell transplantation
- Primary Outcomes
- Safety assessment and stem cell transplant engraftment
- Secondary Outcomes
- Improvements in motor function and development
What is FBX-101?
FBX-101 is an innovative gene therapy being developed to treat infantile Krabbe disease. It is also known by its scientific name, AAVrh10.hGALC (Adeno-associated virus serotype rh10 containing the human galactosylceramidase gene). This therapy uses a special type of virus, called adeno-associated virus serotype rh10, to deliver a healthy copy of the GALC gene to patients with Krabbe disease.
What is Krabbe Disease?
Krabbe disease, also known as globoid cell leukodystrophy, is a rare genetic disorder that affects the nervous system. It is caused by mutations in the GALC gene, which leads to a deficiency of an important enzyme called galactocerebrosidase. This deficiency results in the destruction of myelin, the protective coating around nerve cells, causing severe neurological problems.
How Does FBX-101 Work?
FBX-101 works by introducing a correct copy of the GALC gene into the patient's cells. The therapy is administered intravenously (through a vein) 21 to 60 days after the patient has received a hematopoietic stem cell transplant (HSCT). The goal is to provide the body with the ability to produce the missing enzyme, potentially slowing or stopping the progression of the disease.
The RESKUE Clinical Trial
FBX-101 is currently being studied in a clinical trial called RESKUE (A Phase 1/2 Clinical Study of Intravenous Gene Transfer with an AAVrh10 Vector Expressing GALC in Krabbe Subjects Receiving Hematopoietic Stem Cell Transplantation). This trial aims to:
- Evaluate the safety of FBX-101 when given to infants with Krabbe disease after stem cell transplantation
- Collect evidence of potential therapeutic benefits
Who is Eligible for the Trial?
The trial is designed for infants with Krabbe disease. Key eligibility criteria include:
- Diagnosis of infantile Krabbe disease, confirmed by specific tests
- Age between 1 day and 12 months at the time of screening
- Eligibility for hematopoietic stem cell transplantation (HSCT)
- Adequate organ function
It's important to note that there are also several exclusion criteria, such as prior gene therapy treatment or certain medical conditions that might interfere with the study.
Potential Benefits of FBX-101
While the primary goal of the RESKUE trial is to assess safety, researchers are also looking for signs of potential benefits. These include:
- Improved probability of achieving independent sitting compared to untreated patients or those receiving only HSCT
- Improvement in gross motor function, as measured by a specific developmental scale
These potential benefits could significantly improve the quality of life for children with Krabbe disease if the therapy proves successful.
Safety Considerations
As with any new treatment, safety is a primary concern. The RESKUE trial will closely monitor participants for any adverse events related to FBX-101. It's important to understand that this is a first-in-human study, which means it's the first time this therapy is being tested in people.
Parents and caregivers should discuss all potential risks and benefits with the research team before deciding to participate in the trial.